Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.16 -0.05 (-0.17%)
Streaming Delayed Price Updated: 1:52 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Peering Into Teva Pharmaceutical Indus's Recent Short Interest ↗
 
Via Benzinga
News headline image
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug ↗
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention. 
Via Benzinga
News headline image
Promising Signs: TEVA PHARMACEUTICAL-SP ADR Setting the Stage for a Breakout. ↗
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
News headline image
Teva Challenges Drug Price Law's Impact On Innovation, Generics ↗
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance. 
Via Benzinga
Topics Economy
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
News headline image
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical ↗
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
News headline image
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva ↗
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily
News headline image
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
News headline image
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug ↗
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives. 
Via Benzinga
News headline image
Tesla, Avinger, Jet.Ai, Teva, And Netflix: Why These 5 Stocks Are On Investors' Radars Ahead Of Christmas ↗
Wall Street experienced a positive start to the Santa Rally season, with all major indices and sectors closing higher in the session ahead of Christmas. 
Via Benzinga
News headline image
Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next ↗
Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025 ↗
Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI) stocks in favor of a drugmaker whose shares are up by 112% for the year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
My Top 10 Portfolio Holdings for 2025 ↗
This combination of growth and value stocks has the potential to outperform the broader market in 2025 (and beyond). 
Via The Motley Fool
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The S&P 500 and Dow Jones Industrial Average dropped by 0.4% and 0.6% respectively, while the Nasdaq 100 declined by 0.3%. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug ↗
Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing. 
Via Investor's Business Daily
News headline image
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? ↗
Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease. 
Via Benzinga
News headline image
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call today at 8:00 a.m. ET (U.S.) 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.